Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
This study evaluated the effects of difelikefalin, a kappa opioid receptor (KOR) agonist, on the inflammatory response and renal dysfunction in a rat model of acute kidney injury induced by renal ischemia–reperfusion (I/R) injury, and compared it with other KOR agonists.
One week after right nephrectomy, rats received one of three drugs (difelikefalin [0.001, 0.01, 0.1 mg/kg, intravenous injection], nalfurafine hydrochloride [0.1, 1 mg/kg, oral administration], or U-50488H [1 mg/kg, intravenous injection]). Thirty minutes later, ischemia was induced in the left kidney by clamping its artery and vein for 45 min. Rats were then transferred to metabolic cages for 24-hour urine collection, and blood was taken at the 24-hour time point. Renal function (blood urea nitrogen [BUN], serum creatinine [SCr], and creatinine clearance [CCr]) and the levels of 23 serum cytokines (IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-10, IL-12, IL-13, IL-17, IL-18, G-CSF, M-CSF, GM-CSF, IFN-γ, TNF-α, GRO/KC, MCP-1, MIP-1α, MIP-3α, RANTES, and VEGF) were assessed, as well as the histopathological evaluation of renal tubular damage.
Compared with the sham group (non-I/R), the vehicle group showed increased BUN and SCr levels, and reduced CCr and renal tubular damage. Difelikefalin improved BUN, SCr, and CCr levels and mitigated renal tubular damage. Similar effects were observed with nalfurafine hydrochloride and U-50488H. Thirteen of 23 serum cytokines were elevated in the vehicle group. Difelikefalin suppressed all elevated cytokines to the same levels as those in the sham group, U-50488H showed moderate efficacy by suppressing 6 of 13 cytokines, and nalfurafine hydrochloride exhibited a poor inhibitory effect, affecting only 1 of 13 cytokines.
These findings indicate that difelikefalin has anti-inflammatory and renoprotective effects in a rat acute kidney injury model, and that there is variable anti-inflammatory efficacy among KOR agonists.
The content of this abstract was submitted to the 69th Annual Meeting of the Japanese Society for Dialysis Therapy, held in June 2024 in Yokohama, and it was published in BMC Nephrology (Takeuchi H, et al. 2025 Jul 1; 26(1): 307).
